Want to see ZTS full AI Analyst Report?
ZTS Stock Chart & Stats
$122.38
$1.04(0.64%)
At close: 4:00 PM EST
$122.38
$1.04(0.64%)
Day’s Range― - ―
52-Week Range$71.47 - $160.48
Previous CloseN/A
Volume625.10K
Average Volume (3M)6.57M
Market Cap
$32.10B
Enterprise Value$57.23K
Total Cash (Recent Filing)$1.94B
Total Debt (Recent Filing)$9.24B
Price to Earnings (P/E)12.7
Beta0.36
Next Earnings
Aug 06, 2026EPS Estimate
1.85Next Dividend Ex-DateN/A
Dividend Yield2.73%
Share Statistics
EPS (TTM)6.04
Shares Outstanding419,228,120
10 Day Avg. Volume5,913,783
30 Day Avg. Volume6,568,645
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)16.75
Price to Sales (P/S)5.89
P/FCF Ratio24.44
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$103.67Price Target Upside-15.29% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)6.88
Revenue Forecast (FY)$9.73B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained high gross and net margins indicate durable pricing power, efficient manufacturing and attractive product mix. This margin profile supports reinvestment in R&D, funds shareholder returns and provides a structural buffer versus cost and competitive pressures over the medium term.
Strong Free Cash Flow GenerationConsistent operating and free cash flow provides durable financial flexibility to fund acquisitions, product development and dividends. FCF exceeding or roughly matching net income signals earnings quality and underpins long-term capital returns and strategic investments.
Durable Livestock/International Growth And M&ABroad-based livestock and international expansion diversifies revenue away from U.S. companion weakness and taps higher-volume markets. Combined with targeted M&A (e.g., genomics) and a sizable product pipeline, this supports a larger addressable market and sustainable growth channels over coming years.
Bears Say
Companion-Animal Weakness And Competitive LossesCompanion animal is a higher-margin segment; sustained declines and share loss to lower-cost alternatives reduce margin mix and long-term revenue potential. Persistent lower clinic traffic and price sensitivity could structurally slow recovery and pressure profitability even if other segments perform well.
Balance-Sheet Inconsistency And Shrinking EquityVolatile leverage and a marked decline in shareholders' equity suggest past heavy financing or capital returns that reduce resilience. Even with recent deleveraging, this inconsistency limits flexibility for large investments or shocks and raises governance questions about capital allocation durability.
Channel Destocking, Timing Shifts And FX VolatilityOngoing channel inventory dynamics, fiscal alignment timing and currency headwinds create recurring revenue volatility and obscure true demand trends. That structural variability complicates forecasting, inventory management and margin planning, increasing execution risk across quarters.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $71.47 and its highest was $160.48 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $32.10B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on May 07, 2026. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.604 by -$0.074.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Overvalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.53 which represents an annual dividend yield of 2.73%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.85.
How many shares outstanding does Zoetis have?
Zoetis has 419,228,120 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.53 in its last earnings report, missing expectations of $1.604. Following the earnings report the stock price went down -21.498%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$103.67 (-15.29% Downside)
$103.67 (-15.29% Downside)
Blogger Sentiment
Bullish
ZTS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 508.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $886.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.17%
12-Months-Change
Fundamentals
Return on Equity
2.73%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
ZTS Revenue Breakdown
20.69% Vaccines
24.73% Parasiticides
18.53% Dermatology
10.94% Anti-infectives
8.87% Pain and sedation
7.36% Other pharmaceuticals
4.58% Animal health diagnostics
2.78% Other non-pharmaceuticals
0.29% Medicated feed additives
1.23% Contract manufacturing & human health
ZTS Stock 12 Month Forecast
Average Price Target
$103.67
▼(-15.29% Downside)
Technical Analysis
Ownership Overview
0.08% Insiders
22.43% Mutual Funds
1.40% Other Institutional Investors
46.63% Public Companies and Individual Investors